...
首页> 外文期刊>Cancer gene therapy >Control of E1A under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-|[Delta]|24RGD
【24h】

Control of E1A under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-|[Delta]|24RGD

机译:在与强直性营养不良基因座绝缘子绝缘的E2F-1启动子下控制E1A可降低溶瘤腺病毒Ad- |Δ| 24RGD的毒性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

We previously described Ad-24RGD as an enhanced-infectivity oncolytic adenovirus that targets tumors with an impaired RB pathway. The common alteration of this pathway in cancer eliminates the interaction of pRB with E2F and releases free E2F to activate E2F-responsive promoters, including the E2F-1 promoter. To improve the selectivity towards RB pathway-defective tumors and reduce the toxicity of Ad-24RGD we aimed to control E1A-24 expression under the E2F-1 promoter. A polyA signal was inserted upstream of the E2F-1 promoter to stop transcription initiated at the adenovirus ITR and packaging signal. The human myotonic dystropy locus insulator (DM-1) was also located between the E1a enhancers and the E2F-1 promoter to further insulate the promoter. The Ad-24RGD derivative containing these insulation sequences expressed less E1a-24 in normal cells and resulted less toxic while maintaining the potent oncolytic activity of the parental virus. These results demonstrate that the human DM-1 inslulator can function in an adenovirus context to maintain heterologous promoter selectivity. The new oncolytic adenovirus presented here may represent a valuable therapeutic option for a broad range of tumors with a deregulated E2F/pRB pathway.
机译:先前我们将Ad-24RGD描述为靶向RB通路受损的肿瘤的增强感染性溶瘤腺病毒。癌症中该途径的常见改变消除了pRB与E2F的相互作用,并释放出游离的E2F以激活E2F响应性启动子,包括E2F-1启动子。为了提高对RB通路缺陷肿瘤的选择性并降低Ad-24RGD的毒性,我们旨在控制E2F-1启动子下的E1A-24表达。在E2F-1启动子的上游插入了polyA信号,以停止在腺病毒ITR和包装信号处启动的转录。人强直性肌营养不良位点绝缘子(DM-1)也位于E1a增强子和E2F-1启动子之间,以进一步隔离启动子。包含这些隔离序列的Ad-24RGD衍生物在正常细胞中表达的Ela-24较少,并且在维持亲本病毒的有效溶瘤活性的同时,产生的毒性也较小。这些结果表明,人DM-1接种物可以在腺病毒环境中发挥功能,以维持异源启动子的选择性。本文介绍的新溶瘤腺病毒可能代表了E2F / pRB途径失调的多种肿瘤的有价值的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号